BUY, SELL, HOLD (2)

2 Penny Stocks Rising on Collaboration Announcements

ATHX shares have had a big year

Jun 7, 2018 at 9:50 AM
facebook X logo linkedin


Small-cap stocks have been generating a lot of buzz recently, and just yesterday we identified three surging penny stocks. We'll keep that trend going today and look into the news surrounding healthcare names Athersys, Inc. (NASDAQ:ATHX) and Ophthotech Corp (NASDAQ:OPHT). Shares of both ATHX and OPHT are making big moves today, after the companies revealed new collaborations.

Athersys, Healios Make Another Agreement

Stem cell expert Athersys is trading up 6.1% at $2.96, already tapping a three-year high of $3.08, thanks to news the company is expanding its collaboration with Japan's Healios. Under the agreement, Healios gets the rights to Athersys' MultiStem therapy for $20 million in fees. This comes after Healios invested roughly $21 million in ATHX back in March.

Today's rally is nothing new for the shares as they've been climbing fast since an early March bottom of $1.29. This news could cause some ATHX short sellers to begin to cover. As it stands now, 8.6% of the float is controlled by short sellers, equating to 18 days' worth of buying power, based on average daily volumes.

Gene Therapy Collaboration Lifts OPHT Stock

Meanwhile, Ophthotech -- which focuses on diseases related to the eye -- is up 31.2% at $3.67, a new annual high, following its announcement of a licensing deal with the University of Florida and University of Pennsylvania to develop gene therapies. This is a much-needed move for OPHT, which had been stuck in a series of lower highs since peaking at $3.60 back in November. On a longer-term basis, the picture is even more troubling, as the shares suffered a monumental bear gap back in late 2016, falling from around $40 to around $5. Not a single analyst currently has a "buy" rating on the security, so if nothing else a sustained push higher could possibly draw some bullish attention from the Street.

 

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.